ArticleDrug design, development and therapy2026

Risk of Bone Mineral Density Loss Associated with GLP-1 Receptor Agonists in Overweight COPD Populations [Letter].

Yiwen Hong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.